Eric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.
Eric Nadler, MD, MDD
Advertisement
Articles by Eric Nadler, MD, MDD
Eric Nadler, MD, MPP, discusses the design and goals of a retrospective study of real-world adoption of atezolizumab immunotherapy in extensive-stage small cell lung cancer.
Advertisement
Latest Updated Articles
Retrospective Study Shows Adoption of Immunotherapy in ES-SCLCPublished: April 1st 2022 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
5
